Harvoni is an antiviral medicine used to treat chronic hepatitis C. It contains the active substances sofosbuvir and ledipasvir.

Harvoni has been approved within the NHS for treatment of Genotype 1. It has also been approved for people with Genotype 4 who have previously had treatment or who have compensated cirrhosis.

How it works

Ledipasvir and sofosbuvir each block a protein which is essential for the hepatitis C virus to multiply: sofosbuvir blocks an enzyme called NS5B RNA-dependent RNA polymerase and ledipasvir blocks a protein called NS5A. 


Studies have shown that 94% to 99% of patients with Genotype 1 treated using Harvoni achieved a sustained viral response (SVR) twelve weeks after treatment. Studies on patients with Genotype 4 have been limited in scope, but 100% of participants achieved SVR after twelve weeks. 

Side effects

The most common side effects when using Harvoni (with or without ribavirin) are fatigue and headache.


Contraindications for Harvoni include but are not limited to: rosuvastatin and St. John’s wort.